- Home
- UCL vs GNLX Comparison
UCL vs GNLX Comparison
Compare UCL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- GNLX
- Stock Information
- Founded
- UCL 2014
- GNLX 2001
- Country
- UCL Hong Kong
- GNLX United States
- Employees
- UCL N/A
- GNLX N/A
- Industry
- UCL Telecommunications Equipment
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- GNLX Health Care
- Exchange
- UCL Nasdaq
- GNLX Nasdaq
- Market Cap
- UCL 144.5M
- GNLX 128.0M
- IPO Year
- UCL 2020
- GNLX 2023
- Fundamental
- Price
- UCL N/A
- GNLX $4.75
- Analyst Decision
- UCL
- GNLX Strong Buy
- Analyst Count
- UCL 0
- GNLX 4
- Target Price
- UCL N/A
- GNLX $17.75
- AVG Volume (30 Days)
- UCL 55.1K
- GNLX 134.5K
- Earning Date
- UCL 11-25-2025
- GNLX 11-13-2025
- Dividend Yield
- UCL N/A
- GNLX N/A
- EPS Growth
- UCL N/A
- GNLX N/A
- EPS
- UCL 0.02
- GNLX N/A
- Revenue
- UCL $89,277,000.00
- GNLX N/A
- Revenue This Year
- UCL N/A
- GNLX N/A
- Revenue Next Year
- UCL $20.86
- GNLX N/A
- P/E Ratio
- UCL $99.63
- GNLX N/A
- Revenue Growth
- UCL 3.72
- GNLX N/A
- 52 Week Low
- UCL $0.80
- GNLX $1.99
- 52 Week High
- UCL $4.19
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- UCL N/A
- GNLX 71.94
- Support Level
- UCL N/A
- GNLX $4.17
- Resistance Level
- UCL N/A
- GNLX $4.83
- Average True Range (ATR)
- UCL 0.00
- GNLX 0.26
- MACD
- UCL 0.00
- GNLX 0.04
- Stochastic Oscillator
- UCL 0.00
- GNLX 92.05
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.